← All trials
NCT05706727
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 23, 2023
- Primary completion
- Apr 29, 2024
- Completion date
- May 15, 2024
- First posted
- Jan 31, 2023
- Last posted
- Oct 6, 2023
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- KIST Medical CollegeLead sponsor
- KIST Medical CollegeOverall official - principal investigator
- KIST Medical CollegeReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.